The Online Investor
Daily M&A
Retiree Portfolio
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com
ChartZero

Slideshow Mega-Mergers: Largest Recent M&A Transactions

By The Online Investor Staff, updated Mon., May. 30, 10:24 AM

Slide #1. Shire plc Baxalta Incorporated

Acquirer: Shire plc (SHPG)
Acquiree: Baxalta Incorporated (BXLT)
Details: Baxalta Incorporated (NYSE:BXLT) today announced the results of a vote on the proposals identified in the definitive proxy statement/prospectus, dated April 18, 2016, at a special meeting of shareholders held earlier this morning relating to the proposed combination with Shire plc (LSE: SHP, NASDAQ:SHPG). Baxalta shareholders approved the definitive merger agreement with Shire, dated as of January 11, 2016, and the merger transaction, with approximately 98.9 percent of shares outstanding cast in favor of the proposal. Earlier today, Shire shareholders of approximately 93.8 percent of the votes cast voted in favor of the adoption of the merger agreement with Baxalta. This represents approximately 75.5 percent of Shire's total outstanding shares of common stock as of 8:00 a.m. (London time) on May 25, 2016, the record date for the special meeting. As announced on January 11, 2016, Baxalta and Shire entered into a definitive merger agreement pursuant to which Shire would acquire Baxalta in a stock and cash transaction. Baxalta stockholder approval and Shire shareholder approval are conditions to the merger. The completion of the transaction remains subject to certain other closing conditions, but the companies expect that this transaction will be completed on or about June 3, 2016.

Shire is a holding company. Through its subsidiaries, Co. is a biopharmaceutical company that develops and markets medicines for patients with rare diseases and other conditions. Co.'s marketed products are in the areas of: neuroscience, which includes YVANSE (lisdexamfetamine dimesylate) to treat Attention Deficit Hyperactivity Disorder and BUCCOLAM for Epilepsy; gastrointestinal diseases such as LIALDA (mesalamine) for ulcerative colitis and RESOLOR (prucalopride) for chronic constipation in women; rare diseases such as REPLAGAL (agalsidase alfa) for Fabry disease; and in other therapeutic areas such as FOSRENOL (lanthanum carbonate) for hyperphosphatemia in end stage renal disease.

Open the SHPG Page at The Online Investor »

Shire is a holding company. Through its subsidiaries, Co. is a biopharmaceutical company that develops and markets medicines for patients with rare diseases and other conditions. Co.'s marketed products are in the areas of: neuroscience, which includes YVANSE (lisdexamfetamine dimesylate) to treat Attention Deficit Hyperactivity Disorder and BUCCOLAM for Epilepsy; gastrointestinal diseases such as LIALDA (mesalamine) for ulcerative colitis and RESOLOR (prucalopride) for chronic constipation in women; rare diseases such as REPLAGAL (agalsidase alfa) for Fabry disease; and in other therapeutic areas such as FOSRENOL (lanthanum carbonate) for hyperphosphatemia in end stage renal disease.

Open the BXLT Page at The Online Investor »

Company Name:  Shire Plc (Jersey)
Website:  www.shire.com
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding SHPG:  7
Total Market Value Held by ETFs:  $107.58M
Total Market Capitalization:  $35.48B
% of Market Cap. Held by ETFs:  0.30%
Company Name:  Baxalta Inc
Stock buyback:  BXLT buyback
Website:  www.baxalta.com
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding BXLT:  77
Total Market Value Held by ETFs:  $995.05M
Total Market Capitalization:  $31.25B
% of Market Cap. Held by ETFs:  3.18%
 

May 30, 2016    10:24 AM Eastern
Quotes delayed 20 minutes


Mega-Mergers | www.TheOnlineInvestor.com | Copyright © 1998 - 2016, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.